Canine Arthritis Treatment Market Size, Share and Global Trend By Product (Surgical Procedures, Medications, Nutritional Therapy, Others), and Regional Forecast, 2024-2032

Canine arthritis is one of the commonly occurring chronic illness in dogs that is caused due to prolonged erosion of joints. Prolonged physical activities such as walking, running, and jumping, damages the bone cartilage, resulting in friction within bones. This friction further causes inflammation and pain. Canine arthritis is one of the degenerative joint diseases that cause spinal issues, muscle atrophy, and tiredness in dogs.

There are certain types of canine arthritis, such as osteoarthritis, septic arthritis, and immune-mediated polyarthritis. Due to increasing ownership of canines as a pet, especially due to the animal adoption programs, the market is further anticipated to grow. These trends are further expected to contribute to the growth of the canine arthritis treatment market.

Rising prevalence of arthritis amongst dogs and the increasing pet ownership are the prominent factors for the growth of the global canine arthritis treatment market. Also, certain conditions such as obesity, lack of nutritious food, fatal injuries & accidents, diabetes, prolonged intake of steroids and hyper-laxity are expected to increase the prevalence of canine arthritis, which offers higher potential for growth of the canine arthritis treatment market.

Dog ownership is growing across the world. According to the European Pet Food Federation, Europe registered a growth of an estimated 4.24% in the ownership of dogs during 2016-2017. The number of pet dogs in Europe grew from 63.7 million in 2016 to 66.4 million in 2017. Along with all these factors, the aging of dogs is primarily expected to drive the global canine arthritis treatment market during the forecast period.

Certain factors such as difficulty in the diagnosis of canine arthritis are restraining the growth of the global canine arthritis treatment market during the forecast period. Other limiting factors include the lack of awareness and the increasing costs of canine healthcare.

Key Players Covered

Some of the major companies that are present in the global canine arthritis treatment market are Zoetis, Bayer AG, Boehringer Ingelheim International GmbH, Norbrook, Vetoquinol SA, Ceva, Elanco, and others.

SEGMENTATION

Among the segmentation, medications in the product segment are projected to hold a considerable share of the global canine arthritis treatment market due to higher adoption of medications for canine arthritis treatment in developed as well as developing countries.

Key Insights

• Regulatory scenario for key countries
• Pricing analysis of key players in major countries/regions
• Overview of prevalence of canine arthritis
• Recent industry developments such as partnerships, mergers, and acquisitions
• Recent advances in canine arthritis treatment

Regional Analysis

North America dominated the global canine arthritis treatment market owing to the rise in prevalence of canine arthritis and the rise in ownership of pet dogs. According to the American Pet Products Association, an estimated 94.2 million cats and 89.7 million dogs are owned by households in the U.S. during 2017. The Asia Pacific and Middle East & Africa hold huge potential for growth of the global canine arthritis treatment market owing to rising ownership of dogs and growing awareness of canine arthritis. Also growing veterinary healthcare infrastructure in emerging nations such as India and China are projected to increase the demand for global canine arthritis treatment market during the forecast period.

Key Industry Developments

• In November 2018, announced the launch of the product offering of Osteopen (pentosan polysulphate sodium) for the treatment of canine arthritis and degenerative joint disease
• In May 2018, PetVivo Holdings, Inc. announced the commercial launch of their product offering of The Carti-Cush System (formerly, Kush System), a veterinary device which enables the reinforcement of articulating cartilage tissue for the treatment and further prevention of osteoarthritis in canines